Search Results
228 items found for "Omass Therapeutics"
- A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in...
August 2022 A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE)--Aug. 8, 2022-- Karuna Therapeutics , Inc.
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
March 2022 " Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics
- Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research
We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage
- Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas ...
Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve genomic and transcriptomic profiles of ORs in glioma, we suggest that ORs are potential biomarkers and therapeutic
- Addex Raises $10 Million In Equity Financing
December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq
- Addex raises $4.2 million in equity financing
July 2022 " Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics " Tim Dyer is the Co-Founder and CEO of Addex Therapeutics , which is focusing on the pharmacology
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
Phase 1 studies in Japan with JNJ-40411813 (ADX71149) " Geneva, Switzerland, November 15, 2021 – Addex Therapeutics
- Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future
Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic
- Developing the Cannabinoid Receptor 2 (CB2) pharmacopeia: past, present, and future
Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics
- GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between ...
Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic Given the tremendous success of GPCRs as therapeutic targets, considerable focus has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors.
- Integrative model of the FSH receptor reveals the structural role of the flexible hinge region
September 2022 "The follicle-stimulating hormone receptor (FSHR) belongs to the glycoprotein hormone receptors, a subfamily of G-protein-coupled receptors (GPCRs). FSHR is involved in reproductive processes such as gonadal development and maturation. Structurally, the extensive extracellular domain, which contains the hormone-binding site and is linked to the transmembrane domain by the hinge region (HR), is characteristic for these receptors. How this HR is involved in hormone binding and signal transduction is still an open question. We combined in vitro and in situ chemical crosslinking, disulfide pattern analysis, and mutation data with molecular modeling to generate experimentally driven full-length models. These models provide insights into the interface, important side-chain interactions, and activation mechanism. The interface indicates a strong involvement of the connecting loop. A major rearrangement of the HR seems implausible due to the tight arrangement and fixation by disulfide bonds. The models are expected to allow for testable hypotheses about signal transduction and drug development for GPHRs." Read more at the source #DrGPCR #GPCR #IndustryNews
- 📰 GPCR Weekly News, June 12 to 18, 2023
GPCRs in Neuroscience Orphan receptor GPR88 as a potential therapeutic target for CNS disorders - an Industry News Coherus to Acquire Surface Oncology Confo Therapeutics and AbCellera partner on GPCR-targeting Patent in Japan Proteros Biostructures GmbH Revolutionizes Metabolic Disorder Treatments Structure Therapeutics (June 28 - 30, 2023) NEW FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics 2024) GPCR Jobs NEW Professor in Cardiovascular Pharmacology Scientist I / Scientist II DOE (Native Mass
- 📰 GPCR Weekly News, December 11 to 17, 2023
This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Study Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative
- 📰 GPCR Weekly News, February 20 to 26, 2023
Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics and Pharmacology Scientist/Senior Scientist (Research Software Engineer) Senior Scientist – Native Mass Spectrometry Speculative Applications (Protein Biochemistry) Speculative Applications (Mass Spectrometry
- 📰 GPCR Weekly News, June 26 to July 2, 2023
GPCR Partner, Domain Therapeutics, for their nomination of the best-in-class CCR8 antibody candidate, History and function of the lactate receptor GPR81/HCAR1 in the brain: a putative therapeutic target G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening Clinical Operations Professor in Cardiovascular Pharmacology Scientist I / Scientist II DOE (Native Mass
- 📰 GPCR Weekly News
future perspectives Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic patient-derived xenografts of colorectal carcinoma in mice Methods & Updates in GPCR Research Middle-Down Mass Research Term Of Substance Use Disorder Gabab Positive Allosteric Modulator Discovery Collaboration Domain Therapeutics
- 📰 GPCR Weekly News, June 19 to 25, 2023
GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. function" (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics 29, 2024) GPCR Jobs Professor in Cardiovascular Pharmacology Scientist I / Scientist II DOE (Native Mass
- Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids
interacting with the Glucagon receptor (GCGR), which constitutes an important target for diabetes and obesity therapeutics In this work, we applied MD simulations supported by native mass spectrometry (nMS) to study lipid interactions
- 📰 GPCR Weekly News, March 13 to 19, 2023
GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists Reviews, GPCRs, and more The leukotriene B4 receptors BLT1 and BLT2 as potential therapeutic targets. G protein-coupled receptor pharmacology - insights from mass spectrometry. It Will Participate For H1 2023 Learn more about Exscientia new pipeline candidate, EXS74539 Domain Therapeutics women-men professional equality index Octant introduces Hypatia, their New Robotic Drug Hunter GPCR Therapeutics
- 📰 GPCR Weekly News, February 6 to 12, 2023
IPO, raising $161M 3-drug combo leads to 'unprecedented' response in pancreatic cancer models Addex Therapeutics in ADX71149 Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics and Pharmacology Scientist/Senior Scientist (Research Software Engineer) Senior Scientist – Native Mass Spectrometry Speculative Applications (Protein Biochemistry) Speculative Applications (Mass Spectrometry